

Market Applicability				
Market	GA	MD	NJ	NY
Applicable	X	X	X	X

# Antihypertensive Oral Solution

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
CaroSpir (spironolactone oral suspension) Epaned (enalapril oral solution) Qbrelis (lisinopril oral solution)	May be subject to quantity limit

## APPROVAL CRITERIA

Requests for antihypertensive oral solutions and suspensions may be approved if the following criteria is met:

- I. Individual is unable to swallow the oral tablet dose form due to a clinical condition including but not limited to the following:
  - A. Dysphagia; **OR**
  - B. Individual's age.

**Note:**

ACE inhibitors have a black box warning for fetal toxicity. Agents that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, the ACE inhibitor should be discontinued as soon as possible.

**Key References:**

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: April 16, 2021.
2. Drug Facts and Comparisons. Facts and Comparisons [database online]. St. Louis, MO: Wolters Kluwer Health, Inc; 2021. Updated periodically.
3. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2018;71:e127–248.

PAGE 1 of 2 09/02/2021  
New Program Date 05/09/2018

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability				
Market	GA	MD	NJ	NY
Applicable	X	X	X	X

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

PAGE 2 of 2 09/02/2021  
New Program Date 05/09/2018

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.